Overview

Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients

Status:
Not yet recruiting
Trial end date:
2028-02-29
Target enrollment:
Participant gender:
Summary
Hematologic improvement of erythrocytes after 6 months of canakinumab treatment.
Phase:
Phase 2
Details
Lead Sponsor:
University of Leipzig
Collaborator:
Novartis Pharmaceuticals